Skip to NavigationSkip to content

Advaxis Chief Financial Officer resigns

Published on: 08/09/20

Molly Henderson, the Chief Financial Officer and Executive Vice President of Advaxis, has announced her resignation that will take effect at the end of September.

Henderson has resigned to pursue a new business opportunity. Kenneth A. Berlin, Advanxis’ President and Chief Executive Officer, will serve as interim CFO until a new person can be appointed to the position.

Berlin commented on Henderson’s departure: “We are grateful for Molly’s numerous contributions to Advaxis over the past two years. Her exceptional leadership and financial stewardship played an important role in allowing the company to focus its resources on, and advance the development of, our HOT programs. We wish her success in her new endeavour.”

Henderson joined the company from Cedar Cliff in 2018, where she had served as a financial and business consultant to high-growth entrepreneurial companies. She previously worked as the Chief Financial Officer at Lovance Biotherapeutics. Prior to this role, Henderson had worked as the Chief Business & Financial Officer, Senior Vice President of VirtualScopics, Inc and Corporate Controller at Ultralife Corporation.

In terms of education Henderson holds a MBA and a BS in Accounting from the University of Buffalo and she is a licensed certified public accountant.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches